A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Feb 2019
At a glance
- Drugs Olaparib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms LUCY
- Sponsors AstraZeneca
- 25 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 22 Nov 2018 Planned End Date changed from 29 Nov 2020 to 30 Nov 2020.
- 22 Nov 2018 Planned primary completion date changed from 29 Nov 2020 to 30 Nov 2020.